Skip to search formSkip to main contentSkip to account menu

veliparib

Known as: 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide, 2-(2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide, (2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium 
A poly(ADP-ribose) polymerase (PARP) -1 and -2 inhibitor with chemosensitizing and antitumor activities. With no antiproliferative effects as a… 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (1)

ABT 888

Broader (2)

BenzimidazolesPoly(ADP-ribose) Polymerase Inhibitors
NCIt Antineoplastic Agent TerminologyPARP1 protein, human

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
A Phase I/II Study of Veliparib (ABT-888) with Radiation and Temozolomide in Newly Diagnosed Diffuse Pontine Glioma: A Pediatric Brain Tumor Consortium Study.
BACKGROUND A Pediatric Brain Tumor Consortium (PBTC) phase 1/2 trial of veliparib and radiation, followed by veliparib and… 
Highly Cited
2018
Highly Cited
2018
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study
Background Homologous recombination defects in BRCA1/2-mutated tumors result in sensitivity to poly(ADP-ribose) polymerase… 
Highly Cited
2018
Highly Cited
2018
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild‐type BRCA pancreatic ductal adenocarcinoma
A phase 1 trial was used to evaluate a combination of cisplatin, gemcitabine, and escalating doses of veliparib in patients with… 
Highly Cited
2016
Highly Cited
2016
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid…
Purpose: PARP is essential for recognition and repair of DNA damage. In preclinical models, PARP inhibitors modulate… 
Highly Cited
2015
Highly Cited
2015
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
Purpose: Veliparib, a PARP inhibitor, demonstrated clinical activity in combination with oral cyclophosphamide in patients with… 
Highly Cited
2015
Highly Cited
2015
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
BACKGROUND Sensitizing effects of poly-ADP-ribose polymerase inhibitors have been studied in several preclinical models, but a… 
Highly Cited
2015
Highly Cited
2015
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
BACKGROUND Veliparib (ABT-888) is a potent, orally bioavailable, small-molecule inhibitor of the DNA repair enzymes poly ADP… 
Highly Cited
2014
Highly Cited
2014
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer
SummaryAndrogen receptor-mediated transcription is directly coupled with the induction of DNA damage, and castration-resistant… 
Review
2011
Review
2011
Triple negative breast cancer: unmet medical needs
Triple negative breast cancer (TNBC) is an aggressive clinical phenotype characterized by lack of expression (or minimal… 
Review
2011
Review
2011
PARP inhibitor treatment in ovarian and breast cancer.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)